Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: ligand.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2026 | $244.00 | Buy | BofA Securities |
| 12/9/2025 | $270.00 | Buy | Citigroup |
| 4/10/2025 | $143.00 | Buy | Stifel |
| 10/3/2024 | $135.00 | Outperform | Oppenheimer |
| 7/30/2024 | $130.00 | Outperform | RBC Capital Mkts |
| 2/22/2022 | $180.00 → $130.00 | Buy | Benchmark |
| 2/18/2022 | $185.00 → $165.00 | Overweight | Barclays |
| 9/22/2021 | $174.00 → $180.00 | Overweight | Barclays |
| 7/30/2021 | $200.00 → $190.00 | Buy | Roth Capital |
Fastest customizable press release news feed in the world
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Stifel 2026 Boston Cross Sector 1x1 Conference. Management will participate in one-on-one meetings with investors on June 3, 2026 in Boston.Goldman Sachs 47th Annual Global Healthcare Conference. Management will participate in a fireside chat on June 10, 2026 at 10:00 a.m. ET in Miami followed by one-on-one meetings with investors. Investors interested in arranging one-on-one meetings should contact their Stifel or Goldman Sachs representative. About Ligand PharmaceuticalsLigand
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE:MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial presentation at major cardiology conference in Q2 2027 and subsequent marketing application submission to FDA and global regulatory agencies, assuming primary endpoints are met FDA granted a second Breakthrough Device Designation ("BDD") for AVIM Therapy specific to patients with uncontrolled hypertension despite the use of anti-hypertensive medications, and an indication for a pacemakerVirtue Trial sites progressing with site activation and patient enrollment acceleration continuing t
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. "The first few months of 2026 have al
$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest in Orchestra BioMed's future revenue as well as equityFunding supports continued execution of Orchestra BioMed's pivotal trials for Atrioventricular Interval Modulation Therapy ("AVIM Therapy") and Virtue Sirolimus AngioInfusion Balloon ("Virtue SAB") This payment, together with a $20 million investment from Medtronic (NYSE:MDT) announced separately, represents a total of $35 million in fresh strategic capital received on May 1, 2026 under previously disclosed agreements NEW HOPE, Pa., Ma
JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference (Virtual): Ligand CEO Todd Davis and Wes Kaupinen, president and CEO of Ligand portfolio company Palvella Therapeutics, will participate in a fireside chat at 9:30 a.m. ET on May 6, 2026.Bank of America Healthcare Conference (Las Vegas): Management will participate in a fireside chat at 4:20 p.m. PT on May 12, 2026 and be available for one-on-one meetings on May 12, 2026 and May 13, 2026.CJS Securities Spring 1x1 Conference (Virtual): Mana
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate
JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, May 7, 2026 Time: 8:30 a.m. Eastern time Conference Call: United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in NumbersMeeting ID: 304603090 Webcast: Live and replay webcasts of the call are available here. About LigandLigand is a
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Travere Therapeutics, Inc. (NASDAQ:TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. FILSPARI is the first and only medicine approved by the FDA for the treatment of FSGS,
JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development. Both will report to Paul Hadden, Ligand's Senior Vice President of Investments and Business Development. Dr. Renehan comes to the firm from Blackstone Life Sciences, where he served as a Principal. He was previously in healthcare investment banking with Lazard, Inc., and in corporate strategy at Moderna Therapeutics and Flagship Pioneering. Mr. Brown joins Ligand from Third Bridge Group, where he served as Global Team Leader for Heal
JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami): Management will participate in one-on-one meetings March 11, 202638th Annual ROTH Conference (Dana Point, Calif.): Management will present at 1:00 p.m. PT on March 23, 2026Nordic-American Healthcare Conference 2026 (New York): Management will present at 3:45 p.m. ET on March 25, 2026 Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arran
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
DEFA14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
144 - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
10-Q - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
SCHEDULE 13D - LIGAND PHARMACEUTICALS INC (0000886163) (Filed by)
8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
DEFA14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
DEFA14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BofA Securities initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $244.00
Citigroup initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $270.00
Stifel initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $143.00
Oppenheimer initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $135.00
RBC Capital Mkts initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $130.00
Benchmark reiterated coverage of Ligand Pharmaceuticals with a rating of Buy and set a new price target of $130.00 from $180.00 previously
Barclays reiterated coverage of Ligand Pharmaceuticals with a rating of Overweight and set a new price target of $165.00 from $185.00 previously
Barclays reiterated coverage of Ligand Pharmaceuticals with a rating of Overweight and set a new price target of $180.00 from $174.00 previously
Roth Capital reiterated coverage of Ligand Pharmaceuticals with a rating of Buy and set a new price target of $190.00 from $200.00 previously
Barclays reiterated coverage of Ligand Pharmaceuticals with a rating of Overweight and set a new price target of $190.00 from $198.00 previously
Live Leadership Updates
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me
WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p
Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "
LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4D's Audit and Risk Committee and will serve as the Company’s “audit committee financial expert” under SEC and Nasdaq rules. “With over 25 years of extensive senior operational, international and financial management experience in the pharmaceutical and biotechnology industry, Paul will be able to provide 4D pharma with invaluable insights as we continue to execute
This live feed shows all institutional transactions in real time.
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
Live finance-specific insights
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. "The first few months of 2026 have al
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate
JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, May 7, 2026 Time: 8:30 a.m. Eastern time Conference Call: United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in NumbersMeeting ID: 304603090 Webcast: Live and replay webcasts of the call are available here. About LigandLigand is a
Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share1 of $8.00-$9.00 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and twelve months ended December 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. "We delivered strong fourth q
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference ID 3661098 Webcast:Live and replay webcasts of the call are available here. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scienti
Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting childrenImpetigo affects approximately 3 million people in the U.S. every year and is among the most common bacterial skin infections seen in pediatric officesPrivate convertible notes financing will support the acquisition and re-launch of Xepi, accelerate the commercialization of ZELSUVMI for molluscum contagiosum, and for general working capital purposes DURHAM, N.C., Nov. 07, 2025 (GLOBE NEWSWI
JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date:Thursday, November 6, 2025 Time:8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference ID 3661098 Webcast:Live and replay webcasts of the call are available here. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement th
JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, August 7, 2025 Time: 8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference ID 3661098 Webcast:Live and replay webcasts of the call are available here. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement thr
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8
JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025 Time: 8:30 AM Eastern Time Conference Call: (800) 715-9871 (U.S. & Canada) (646) 307-1963 (International) Conference ID 3661098 Webcast: Live and replay webcasts of the call are available here. About Ligand PharmaceuticalsLiga